Esperion Therapeutics, Inc. (ESPR): Price and Financial Metrics

ESPR POWR Grades

• ESPR scores best on the Growth dimension, with a Growth rank ahead of 91.58% of US stocks.
• The strongest trend for ESPR is in Growth, which has been heading up over the past 179 days.
• ESPR ranks lowest in Stability; there it ranks in the 2nd percentile.

ESPR Stock Summary

• Revenue growth over the past 12 months for Esperion Therapeutics Inc comes in at -65.53%, a number that bests only 2.22% of the US stocks we're tracking.
• In terms of volatility of its share price, ESPR is more volatile than 97.85% of stocks we're observing.
• Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ESPR comes in at -86.18% -- higher than that of only 4.72% of stocks in our set.
• Stocks with similar financial metrics, market capitalization, and price volatility to Esperion Therapeutics Inc are LMNL, JAGX, CLPT, WB, and EYPT.
• Visit ESPR's SEC page to see the company's official filings. To visit the company's web site, go to www.esperion.com.

ESPR Valuation Summary

• In comparison to the median Healthcare stock, ESPR's price/sales ratio is 48.02% lower, now standing at 5.9.
• Over the past 100 months, ESPR's price/sales ratio has gone NA NA.
• ESPR's price/sales ratio has moved NA NA over the prior 100 months.

Below are key valuation metrics over time for ESPR.

ESPR Growth Metrics

The year over year cash and equivalents growth rate now stands at 44.99%.
• The 4 year cash and equivalents growth rate now stands at 303.99%.
• The year over year price growth rate now stands at -36.97%.

ESPR's revenue has moved up $78,447,000 over the prior 70 months.

The table below shows ESPR's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-12-31	78.447	-263.809	-269.108
2021-09-30	72.684	-274.653	-308.465
2021-06-30	62.108	-292.155	-324.516
2021-03-31	233.685	-104.898	-156.237
2020-12-31	227.547	-85.177	-143.551
2020-09-30	218.891	-66.621	-101.021

ESPR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• ESPR has a Quality Grade of C, ranking ahead of 47.39% of graded US stocks.
• ESPR's asset turnover comes in at 0.214 -- ranking 191st of 680 Pharmaceutical Products stocks.
• CLDX, JAGX, and CDMO are the stocks whose asset turnover ratios are most correlated with ESPR.

The table below shows ESPR's key quality metrics over time.